Senores Pharmaceuticals Ltd (SENORES) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Senores Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026
Audio / Video · 30 Oct 2026, 12:09 am
Senores Pharmaceuticals Discloses Q2 and H1FY27 Earnings Call Audio Recording Link Senores Pharmaceuticals Limited informed stock exchanges that the audio recording of its earnings conference call held on 29th Oct'26, discussing financial performance for Q2 and H1FY27 (quarter ended 30th Sep'26), has been made publicly available on the company's official website.
Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible ....
Others (Uncategorized) · 29 Oct 2026, 11:01 pm
Senores Pharmaceuticals Reports Zero Deviation in Preferential Issue Fund Utilization Senores Pharmaceuticals confirmed nil deviation in the utilization of proceeds from its preferential issue of 11.70 lakh convertible equity warrants raised on 28th Mar'26 at ₹812 per warrant, totaling ₹95.00 crore. As of 30th Sep'26, the company deployed ₹16.91 crore, including ₹6.84 crore toward working capital, ₹6.15 crore as loans to subsidiaries for working capital, and ₹3.92 crore for general corporate purposes. Product development expenditure allocation of ₹25.00 crore remains unutilized. The statement was reviewed by the Audit Committee and approved on 29th Oct'26.
Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026
Others (Uncategorized) · 29 Oct 2026, 10:58 pm
Senores Pharmaceuticals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter Senores Pharmaceuticals confirmed zero deviation in utilizing its ₹500.00 crore IPO proceeds for the quarter ended 30th Sep'26, as per SEBI Regulation 32. Out of the ₹500.00 crore raised, total funds utilized reached ₹418.83 crore. Key deployments include inorganic growth and corporate purposes (₹161.91 crore), debt repayment (₹93.30 crore), and working capital (₹102.74 crore). Fund allocations adhere to objects approved via prospectus and the 3rd Aug'26 postal ballot, with oversight from monitoring agency CARE Ratings.
Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026
Others (Uncategorized) · 29 Oct 2026, 10:48 pm
Senores Pharmaceuticals Reports Q2FY27 IPO Proceeds Utilization and Object Revisions CARE Ratings' monitoring report for Senores Pharmaceuticals reveals cumulative utilization of Rs. 418.83 crore from its Rs. 500.00 crore fresh IPO proceeds through 30th Sep'26, with Rs. 19.37 crore deployed during Q2FY27. Net unutilized proceeds of Rs. 81.17 crore remain parked primarily in bank fixed deposits. Shareholders approved revisions to issue objects via postal ballot on 4th Aug'26, reallocating funds toward subsidiary ANDA acquisitions (Rs. 15.39 crore) and plant expansions in Vadodara (Rs. 25.00 crore) and Atlanta (Rs. 24.63 crore).
We enclose herewith the Investor Presentation for Q2 & H1FY27
Investor Presentation · 29 Oct 2026, 8:16 pm
Senores Pharmaceuticals Q2 and H1 FY27 Performance Presentation Senores Pharmaceuticals reported consolidated revenue growth of 25% YoY to ₹192.3 Cr in Q2 FY27 and 30% YoY to ₹372.5 Cr in H1 FY27. Regulated markets drove 71% of H1 revenue with ~42% EBITDA margins. Consolidated H1 EBITDA surged 58.2% YoY to ₹111.4 Cr, expanding margins by ~530 bps to 29.9%, while PAT rose 31% YoY to ₹67.0 Cr. Growth was supported by 64 approved ANDAs and forward integration through Zoraya and Amerisyn, targeted to accelerate H2 FY27 performance across US government and B2C channels.
Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company
Change in Auditor · 29 Oct 2026, 7:39 pm
Senores Pharmaceuticals Q2FY27 Results and Joint Statutory Auditor Appointment Senores Pharmaceuticals reported consolidated Q2FY27 revenue of ₹192.33 crore, up 24.9% YoY, with EBITDA surging 38% YoY to ₹58 crore and PAT rising 21.5% YoY to ₹36.60 crore. For H1FY27, revenue climbed 30.0% YoY to ₹372.54 crore, while PAT reached ₹67.05 crore, up 30.7% YoY. Operating cash flow improved to ₹29.22 crore in H1FY27. Management guided for 30–40% revenue growth and 50–60% PAT growth in FY27. Additionally, the board approved appointing M/s Talati and Talati LLP as Joint Statutory Auditors for FY27–FY31.
Senores Pharmaceuticals Limited has informed the exchange regarding media release
Press Release · 29 Oct 2026, 7:35 pm
Senores Pharmaceuticals Reports Strong Q2 and H1 FY27 Performance Senores Pharmaceuticals posted its highest-ever quarterly revenue and EBITDA in Q2FY27, with revenue growing 24.9% YoY to ₹192.3 crore, EBITDA rising 38% YoY to ₹58 crore, and PAT increasing 22% YoY to ₹37 crore. For H1FY27, revenue reached ₹372.5 crore (+30% YoY), while PAT rose 31% YoY to ₹67 crore. Regulated markets drove growth, surging 34.3% YoY in H1FY27 to ₹264.5 crore. Operating cash flow improved to ₹38 crore. Management reaffirmed FY27 guidance of 30–40% revenue growth and 50–60% PAT growth.
Senores Pharmaceuticals Limited has informed the exchange about subsidiary companies capacity expansion
Others (Uncategorized) · 29 Oct 2026, 7:31 pm
Senores Pharmaceuticals Announces Capacity Expansions Across Subsidiaries Senores Pharmaceuticals announced planned capacity expansions across its subsidiaries totaling INR 43.00 Cr, targeted for completion by end of Mar'27. Havix Group INC (USA) will expand capacity from 1.2 Bn to 2.0 Bn units for INR 18.00 Cr, while Apnar Pharma (India) will scale from 0.5 Bn to 1.2 Bn units for INR 20.00 Cr. Additionally, Ratnatris Pharmaceuticals is adding a 2.7 Mn-unit Prefilled Syringe line for INR 5.00 Cr. Funding will be sourced via internal accruals and IPO proceeds to meet growing demand.
Senores Pharmaceuticals Limited has informed the exchange regarding unaudited financial results for quarter ended September 30, 2026
Financial Result · 29 Oct 2026, 7:26 pm
Outcome of Board Meeting held on October 29, 2026
Outcome · 29 Oct 2026, 7:22 pm
Senores Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 192 (+24.9% YoY | +6.7% QoQ) ■ EBITDA: 57.7 (+38.3% YoY | +7.3% QoQ) ■ EBITDA Margin (%): 30.0 (+290 bps YoY | +15 bps QoQ) ■ PAT: 39.5 (+22.0% YoY | +28.5% QoQ) ■ EPS (INR): 8.82 (+34.9% YoY | +33.6% QoQ)
Senores Pharmaceuticals Limited has submitted to the Exchange Outcome of board Meeting held on October 29, 2026
Outcome · 29 Oct 2026, 7:21 pm
We hereby inform you that the timing of the earnings conference call to discuss the financial results for the second quarter of FY 2026-27 (Q2 FY27) has been re-scheduled to 04:00 P.M. ....
Intimation · 23 Oct 2026, 11:42 pm
Senores Pharmaceuticals Reschedules Q2 FY27 Earnings Call to 29th Oct'26 Senores Pharmaceuticals Limited has rescheduled its earnings conference call to discuss Q2 and H1 FY27 financial results. The call, hosted by DAM Capital Advisors Ltd, will now take place at 16:00 hrs IST on 29th Oct'26, advanced from the earlier scheduled time of 17:00 hrs IST. Senior management participants include Promoter & MD Swapnil Shah, Chairman Sanjay Majmudar, and Whole Time Director & CFO Deval Shah. The company confirmed that audio recordings and call transcripts will be made available on its website post-call.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
SENORES PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 29 Oct 2026, 5:30 am
We hereby inform that, post announcement of Un-audited Consolidated and Standalone Financial Results for the quarter and half year ended on September 30, 2026, the Company will hold the ....
Intimation · 29 Oct 2026, 5:00 pm
Senores Pharmaceuticals Schedules Q2 and H1 FY27 Earnings Call Senores Pharmaceuticals Limited will host its Q2 and H1 FY27 post-results earnings conference call on 29th Oct'26 at 17:00 IST, following the release of its un-audited standalone and consolidated financial results for the period ended 30th Sep'26. Organized by DAM Capital Advisors, the call will feature Managing Director Swapnil Shah, Chairman Sanjay Majmudar, and Whole Time Director & CFO Deval Shah to discuss financial performance. Universal dial-in numbers include +91 22 6280 1384 and +91 22 7115 8285, alongside international toll-free options.
Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve 1. The Un-audited ....
Intimation · 29 Oct 2026, 5:30 am
Senores Pharmaceuticals Schedules Board Meeting on 29th Oct'26 for Q2 Results Senores Pharmaceuticals Limited announced that its Board of Directors will meet on 29th Oct'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities has been closed since 1st Oct'26 and will reopen 48 hours after the financial results are approved and submitted to stock exchanges.
The Board at its meeting held today has re-appointed Mr. Swapnil Jatinbhai Shah as the Managing Director of the Company and Mr. Chetan Bipinchandra Shah as the Whole-time Director of the Company.
Change in Management · 13 Oct 2026, 5:53 pm
Senores Pharmaceuticals Re-Appoints Managing Director and Whole-Time Director for Three-Year Terms The Board of Directors of Senores Pharmaceuticals Limited approved the re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for a three-year term effective 15th Oct'26. Additionally, the Board approved the re-appointment of Mr. Chetan Bipinchandra Shah as Whole-Time Director for three consecutive years starting 10th Nov'26. Both directors are liable to retire by rotation, and the appointments are subject to shareholder approval via postal ballot. Neither director is related inter-se to any other board members or debarred by SEBI.
The Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has approved the following: 1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) ....
Others (Uncategorized) · 13 Oct 2026, 5:48 pm
Senores Pharmaceuticals Approves Re-Appointment of Managing Director and Whole-Time Director The Board of Directors of Senores Pharmaceuticals Limited approved the re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for a three-year term effective 15th Oct'26, liable to retire by rotation. Additionally, the Board approved the re-appointment of Mr. Chetan Bipinchandra Shah as Whole Time Director for three consecutive years effective 10th Nov'26, also liable to retire by rotation. Both key leadership appointments remain subject to shareholder approval via a postal ballot process.
Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting
Annual General Meeting · 28 Sept 2026, 5:01 pm
Proceedings of the 9th Annual General Meeting of the Company held on September 25, 2026
Annual General Meeting · 25 Sept 2026, 10:20 pm
Clarification Letter on volume movement in the scrip of the Company
Others (Uncategorized) · 21 Sept 2026, 5:29 pm
Senores Pharmaceuticals Clarifies Stock Volume Movement to Exchanges Senores Pharmaceuticals clarified on 21st Sep'26 regarding recent volume movement in its scrip on the BSE and NSE. The company confirmed compliance with SEBI (LODR) Regulations, stating that it has promptly reported all material information affecting operations or performance. Management confirmed there is no undisclosed or price-sensitive information, impending announcement, or corporate action requiring disclosure that could have triggered the volume fluctuation. The company reiterated its commitment to promptly notify exchanges of any future material developments.
The Exchange has sought clarification from Senores Pharmaceuticals Ltd on September 21, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 21 Sept 2026, 5:04 pm
We are pleased to announce that the USFDA has successfully completed its inspection at the manufacturing facility of Apnar Pharma Private Limited
Others (Uncategorized) · 11 Sept 2026, 7:12 pm
Senores Pharmaceuticals Subsidiary Successfully Completes USFDA Inspection at Vadodara Facility The USFDA successfully completed an inspection at the Vadodara manufacturing facility of Apnar Pharma Private Limited, a subsidiary of Senores Pharmaceuticals Limited. Conducted from 7th Sep'26 to 11th Sep'26, the audit concluded with zero GMP-related observations and only one minor procedural observation. The subsidiary will submit its formal response within the stipulated timeframe, posing minimal regulatory risk to ongoing manufacturing operations.
We are submitting herewith the Corrigendum to the Annual Report of the Company for the financial year 2025-26.
Others (Uncategorized) · 09 Sept 2026, 10:45 pm
We are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.
Others (Uncategorized) · 03 Sept 2026, 10:38 pm
Senores Pharmaceuticals Releases FY26 Business Responsibility and Sustainability Report Senores Pharmaceuticals filed its FY26 BRSR for the year ending Mar'26. Standalone turnover reached INR 10,609 lakhs, alongside a net worth of INR 74,990 lakhs. Exports contributed 43.95% to total turnover. Highlighting strong operational compliance, the company reported zero regulatory penalties, product recalls, or data breaches during the year. Environmentally, Senores maintained its Zero Liquid Discharge status at the Mehsana plant and recorded total non-renewable energy consumption of 22.50 Tera Joules. Management confirmed full adherence to environmental and labor regulations with no pending stakeholder complaints.